MedTrace Logo

Evaluation of Intranasal Naltrexone and Naloxone

NCT03851731 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-09-14

No results posted yet for this study

Summary

This study will be to determine the pharmacokinetics of naltrexone and naloxone when administered via intranasal separately and in combination in healthy volunteers.

Conditions

  • Opioid-use Disorder

Interventions

DRUG

Naltrexone

Intranasal spray

DRUG

Naloxone

Intranasal spray

DRUG

Naltrexol

Intranasal spray

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Nora Chiang, PhD · NIH / NIDA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-05
Primary Completion
2015-11-07
Completion
2015-11-07
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03851731 on ClinicalTrials.gov